Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BAC has entered into an agreement with Bristol-Myers Squibb (BMS) to produce CaptureSelect affinity ligands for applications in the purification and analysis of Adnectins.
Subscribe to our email newsletter
Adnectins are designed by using BMS‘ proprietary PROfusion technology to either block or stimulate the action of specific targets across a range of therapeutic areas.
Under the agreement, BAC and BMS will work together to discover and develop CaptureSelect ligands for the routine purification of Adnectin biologics.
BAC CEO Laurens Sierkstra said their CaptureSelect platform enables them to produce ligands that have high affinity and specificity for individual proteins and facilitates the generation of an exceptionally pure product in a single purification step.